GLP-1 and ADC rollercoasters pick up speed
Podcast: BioSpacePublished On: Wed Dec 06 2023
Description: The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, AbbVie buys ImmunoGen for a cool $10B and scores a win with Teliso-V as ADC momentum continues to build. Plus, the FDA investigates malignacies linked to CAR-T. BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.
The note was deleted
The note was saved
Your message was sent